色噜噜狠狠一区二区三区Av蜜芽,,四川少妇搡BBBB搡BBBB,韩日产理伦片在线观看,91丨露脸丨熟女
中文
中文
為了病患而驅(qū)動的創(chuàng)新
Patient-first cell therapy innovation
 

Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy
  • 0


On the cover: 
The transdifferentiation paths of erythroid precursor cells (EPCs) under the influence of tumor is delineated from Palantir algorithm‐based single-cell transcriptomic trajectory analysis (Long et al., 674–693), and embedded into artwork inspired by Wassily Kandinsky's “Composition 8.” As acquired “organs,” tumors exert a self-beneficial influence on the immune system by hijacking of erythropoiesis for myelopoiesis. Besides exacerbating anemia, CD45+ EPCs transdifferentiation generates myeloid cells that robustly curtail anti‐tumor immunity. Clinically, the abundance of these converted cells predicts immune tolerance in many human tumor types and resistance to immune checkpoint inhibitor treatment. Design and painting by Yijie Hou. Conceptual visualization by Qi-Jing Li and Bo Zhu.

https://www.cell.com/cancer-cell/current#closeFullCover

 

Copyright ? 2019 天科雅生物醫(yī)藥科技有限公司

粵公網(wǎng)安備 44011502000528號

粵ICP備20056630號 Powered by vancheer
關(guān)于天科雅
研究與發(fā)展
產(chǎn)品及臨床
新聞與媒體
招賢納士

Copyright ? 2019 天科雅生物醫(yī)藥科技有限公司

粵公網(wǎng)安備 44011502000528號

粵ICP備20056630號 Powered by vancheer